Cover Image
Market Research Report
Product code 
755508

Global Atrial Fibrillation Market - 2022-2029

Published: | DataM Intelligence | 200 Pages | Delivery time: 2 business days

Price

Back to Top
Global Atrial Fibrillation Market - 2022-2029
Published: May 7, 2022
DataM Intelligence
Content info: 200 Pages
Delivery time: 2 business days
  • Description
  • Table of Contents

Market- Overview

The global atrial fibrillation market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX% during the forecast period (2022-2029).

Atrial Fibrillation is the most common heart condition caused due by irregular and rapid heart rate and causes poor blood flow and can cause heart failure and stroke. Atrial fibrillation is the most commonly detected arrhythmia in modern clinical practice and is responsible for nearly 30% of hospital admissions related to cardiac rhythm problems.

Market Dynamics

The global atrial fibrillation market growth is driven by the Increased usage of generics, raising awareness about the disease, and the growing focus of companies in emerging nations are some of the key trends in the atrial fibrillation market.

The rising burden of obesity and heart diseases drives the market growth

The atrial fibrillation market is driven by the rising prevalence of obesity and heart diseases across the globe. Additionally, heart diseases are one of the major causes of mortality across the globe, and due to the changing lifestyle, the number of people suffering from heart diseases is growing rapidly. Obesity is associated with an increased risk of developing cardiovascular disease (CVD), particularly heart failure (HF) and coronary heart disease (CHD). The mechanisms through which obesity increases CVD risk involve changes in body composition that can affect hemodynamics and alters heart structure. Pro-inflammatory cytokines produced by the adipose tissue itself can induce cardiac dysfunction and can promote the formation of atherosclerotic plaques.

Atrial Fibrillation (AFib) is the most prevalent chronic arrhythmia in patients above 65 years of age. As per the Centers for Disease Control and Prevention (CDC) estimates, around 12.1 million people in the United States will have AFib by 2030. With the growth in the aging population, this number is expected to increase. Thus, the increasing incidences of CVD and atrial fibrillation are expected to augment the growth of the market studied and are posing a high burden on the economies of various countries due to the high cost of treatment. Hence, owing to the aforementioned factors, the market studied is expected to grow in the forecast period.

Complications associated with atrial fibrillation will hamper the growth of the market

However, atrial fibrillation is a serious diagnosis. While this condition isn't fatal in itself, it can lead to potentially life-threatening complications. Two of the most common complications of atrial fibrillation are stroke and heart failure, both of which can be fatal if not managed quickly and effectively.

COVID-19 Impact Analysis

COVID-19 patients with cardiovascular disorders are at high risk and are most vulnerable to multiple organ failures, including myocarditis and rhythm disturbance. The data from Wuhan, China, has indicated that arrhythmia and acute cardiac injury were amongst the most prevalent heart complications in confirmed-positive cases of COVID-19. Furthermore, the February 2020 case report in the Journal of the American Medical Association (JAMA) identified common complications, such as shock (8.7%), acute respiratory distress syndrome (19.6%), arrhythmia (16.7%), and acute cardiac injury (17.2%) among hospitalized patients. Moreover, patients who received care in the ICU were more likely to have one of these complications than non-ICU patients.

Moreover, owing to the evolving public health crisis of COVID-19, remote monitoring allows clinicians to maintain necessary patient rapport with their healthcare provider when required. Healthcare providers can access information remotely about a patient's health while the patient is at home, which will reduce the need for hospital visits and minimize the risk of expos-19. The article 'Home Monitoring of Cardiac Devices in the Era of COVID-19', published in 2020, concluded that new technologies and digital platforms to aid in remote care should be developed and further research on the role of telehealth, continuous data collecting, advanced automotive features, and remote patient monitoring is needed to guide best practices, which may fuel the growth of the market in the forecast period.ure to COVID

Segment Analysis

The ambulatory surgical center's segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The ambulatory surgical center segment is expected to witness good growth due to enhanced healthcare infrastructure, availability of skilled labor, and affordability. The rising patient pool and growing geriatric population suffering from lifestyle diseases, such as atherosclerosis and heart failure, are expected to propel the market. However, compared to conventional surgeries, the benefits of minimally invasive surgeries will ultimately lead to segment growth. Benefits, such as reduced surgical pain, injury, hospital stay, higher accuracy, and speedy recovery time, are encouraging patients to opt for minimally invasive surgeries, which is expected to boost the market growth.

In addition, owing to the increasing burden of obesity, there is an increase in the number of people suffering from atrial fibrillation. Hence, it is believed that an increased prevalence of obesity is contributing to the growth of the market.

Geographical Analysis

North America region holds the largest market share of the global atrial fibrillation market

The North American region is expected to dominate the atrial fibrillation market. This is majorly attributed to the rising patient pool in the region and the presence of key players. As per the statistics provided by the CDC (Centre for Disease Control and Prevention), in 2017, around 2.7 to 6.1 million people in the United States had atrial fibrillation, and with the rising geriatric population, it is expected that the demand for the studied market will grow in the future. As per American Heart Association (2018), high blood pressure was one of the leading causes of atrial fibrillation that accounting for approximately 14-22% of all atrial fibrillation cases in the United States.

With the presence of key players in the country, technological advancements and the availability of favorable insurance policies are augmenting the growth of the market studied in the United States. For instance, in July 2020, Boston Scientific Corporation announced that it received US FDA approval for the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device, which is indicated to reduce the risk of stroke in patients with non-valvular atrial fibrillation (NVAF) who requires alternative to oral anticoagulation therapy.

Competitive Landscape

The atrial fibrillation market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Boston Scientific Corporation, Medtronic PLC, Biotronik SE & Co. KG, AtriCure Inc., Cardiofocus Inc., Abbott Laboratories, Advansta Inc., Johnson & Johnson, MicroPort Scientific Corporation, Koninklijke Philips NV, Siemens AG, Osypka AG, among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the atrial fibrillation market globally. For instance, in March 2021, Tempus announced that the US FDA granted the company Breakthrough Device Designation for its ECG Analysis Platform. The platform, developed in collaboration with Geisinger, aids clinicians in identifying patients at increased risk of developing atrial fibrillation (AFib) or atrial flutter.

Boston Scientific Corporation

Overview:

Boston Scientific Corporation develops, manufactures, and markets minimally invasive medical devices. The Company's products are used in interventional cardiology, cardiac rhythm management, peripheral interventions, electrophysiology, neurovascular intervention, endoscopy, urology, gynecology, and neuromodulation.

Product Portfolio:

Maestro 4000 Cardiac Ablation System: The Open-Irrigated (OI) System Empowers Irrigated Ablation Procedures. OI System empowers your ability to maximize open-irrigated procedure success and helps drive improvement in patient outcomes with the most advanced ablation technology.

Why Purchase the Report?

Visualize the composition of the global atrial fibrillation market segmentation by surgery procedures, non-surgical procedures, end-user, and region highlighting the key commercial assets and players.

Identify commercial opportunities in the global atrial fibrillation market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global atrial fibrillation market-level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global atrial fibrillation market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Market Segmentation

Global Atrial Fibrillation Market- By Surgery Procedures

Maze Surgery

Catheter Ablation

Global Atrial Fibrillation Market- By Non-Surgical Procedures

Electric Cardioversion

Pharmacological Drugs

Diagnostic Devices

Mapping and Recording Systems

Cardiac Monitors

Access Devices

Left Atrial Appendage

Closure Devices

Global Atrial Fibrillation Market- By End User

Hospitals

Ambulatory Surgical Centers

Other

Global Atrial Fibrillation Market- By Region

North America

Europe

Asia-Pacific

Middle East & Africa

South America

Product Code: DMMD446

Table of Contents

1. Global Atrial Fibrillation Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Atrial Fibrillation Market-Market Definition and Overview

3. Global Atrial Fibrillation Market- Executive Summary

  • 3.1. Market Snippet By Surgery Procedures
  • 3.2. Market snippet By Non-Surgical Procedures
  • 3.3. Market Snippet By End User
  • 3.4. Market Snippet by Region

4. Global Atrial Fibrillation Market-Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising Burden of Obesity and Heart Diseases
      • 4.1.1.2. Rising Number of Programs to Enhance Public Awareness
    • 4.1.2. Restraints:
      • 4.1.2.1. Complications associated with atrial fibrillation
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Atrial Fibrillation Market- Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. Global Atrial Fibrillation Market- COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. Global Atrial Fibrillation Market- By Surgery Procedures

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Surgery Procedures Segment
    • 7.1.2. Market Attractiveness Index, By Surgery Procedures Segment
  • 7.2. Maze Surgery *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Catheter Ablation

8. Global Atrial Fibrillation Market- By Non-Surgical Procedures

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Non-Surgical Procedures
    • 8.1.2. Market Attractiveness Index, By Non-Surgical Procedures
  • 8.2. Electric Cardioversion*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Pharmacological Drugs
  • 8.4. Diagnostic Devices
  • 8.5. Mapping and Recording Systems
  • 8.6. Cardiac Monitors
  • 8.7. Access Devices
  • 8.8. Left Atrial Appendage
  • 8.9. Closure Devices

9. Global Atrial Fibrillation Market- By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User Segment
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Ambulatory Surgical Centers
  • 9.4. Others

10. Global Atrial Fibrillation Market- By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Surgery Procedures
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Non-Surgical Procedures
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Surgery Procedures
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Non-Surgical Procedures
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Surgery Procedures
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Non-Surgical Procedures
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Surgery Procedures
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Non-Surgical Procedures
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Surgery Procedures
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Non-Surgical Procedures
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Global Atrial Fibrillation Market- Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking

12. Global Atrial Fibrillation Market- Company Profiles

  • 12.1. Boston Scientific Corporation*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Medtronic PLC
  • 12.3. Biotronik SE & Co. KG
  • 12.4. AtriCure Inc.
  • 12.5. Cardiofocus Inc.
  • 12.6. Abbott Laboratories
  • 12.7. Advansta Inc.
  • 12.8. Johnson & Johnson
  • 12.9. MicroPort Scientific Corporation
  • 12.10. Koninklijke Philips NV
  • 12.11. Siemens AG
  • 12.12. Osypka AG

LIST NOT EXHAUSTIVE

13. Global Atrial Fibrillation Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us